10 results about "Salmeterol" patented technology

The present disclosure provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. Salmeterol or a pharmaceutically acceptable salt thereof may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. Also provided are methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. The present disclosure further provides methods comprising administering salbutamol or a pharmaceutically acceptable salt thereof. Salmeterol, salbutamol, or a pharmaceutically acceptable salt thereof may be administered conjointly with other FDA-approved drugs such as luspatercept, lenalidomide, daprodustat, vadadustat, an erythropoiesis-stimulating agent (ESA), and / or a hypomethylating agent.

The invention relates to an inhalation dry powder preparation containing a salmeterol and tiotropium salt composition and a preparation method of the inhalation dry powder preparation, and belongs to the technical field of pharmaceutical preparations. The preparation comprises a long-acting beta-2 adrenergic receptor agonist (LABA) salmeterol and a long-acting anticholinergic drug (LAMA) tiotropium salt, and the efficient synergistic effect of the two drugs is achieved by optimizing a drug micronization process, a carrier particle design, a carrier material and a preparation process. The medicine can penetrate into a lung target region, so that precise treatment is realized. A powder mist inhalation device CN219423486U disclosed by Nanchang large pharmaceutical industry limited company is adopted as a delivery device, and the lung deposition rate and delivery efficiency of the medicine are remarkably improved by controlling the particle size of the medicine, the particle property of a carrier and the uniformity of the preparation. In addition, the invention further provides a preparation method of the preparation, the preparation method comprises the processes of medicine micronization, mixing homogenization and packaging, and the stability and dosage accuracy of the preparation are ensured. Experiments show that in an accelerated stability investigation period as long as 6 months, the drug content, impurity level and fine particle fraction in the preparation are kept stable and do not change significantly, and it is proved that the preparation has good physical and chemical stability and storage performance. The preparation has quick-acting and long-acting bronchiectasia effects, is suitable for long-term management of moderate and severe asthma and chronic obstructive pulmonary disease (COPD), and can significantly improve the medication convenience and treatment compliance of patients.

The present invention provides a preparation method and application of salmeterol, relating to the technical field of chemical synthesis. Using p-methoxyacetophenone as a raw material, salmeterol is obtained through ammoniation reaction, substitution reaction, formylation reaction, etherification reaction, reduction and hydrolysis reaction in sequence. The raw materials of the present invention are cheap and easily available, and the reagents used are conventional commercially available reagents, avoiding the cumbersome or difficult-to-control reaction steps such as deprotection and reduction using palladium carbon in the prior art, and avoiding the use of toxic and harmful reagents such as bromine. The reaction conditions of the present invention are mild, the reaction process is easy to control, the operation is safe, the safety factor is high, the production cost is saved, the obtained product has a high yield and high purity, and a process route for industrial production of a product with higher quality is provided.

The invention belongs to the technical field of biological medicine, and particularly relates to combined application of salmeterol and an FASN inhibitor in preparation of a medicine for treating lung cancer. Compared with a single-drug FASN inhibitor, the use of the salmeterol combined FASN inhibitor has multiple advantages. It is found for the first time that the salmeterol combined with the FASN inhibitor can improve the treatment effect of the FASN inhibitor on lung cancer, the drug resistance of lung cancer cells is reduced, and the lifetime of a patient is prolonged. In addition, the salmeterol is combined with the FASN inhibitor, so that the side effect of the FASN inhibitor can be reduced, the salmeterol targeted lung cancer cells are more specific, non-specific injury can be avoided, and the living quality of patients is improved.

Described herein are methods for treating COVID-19 or preventing COVID-19 in a subject exposed to SARS-CoV-2 by administering to the subject a therapeutically effective amount of salmeterol or the pharmaceutically acceptable salt thereof.

The invention discloses a salmeterol patch and a preparation method thereof. The preparation method comprises the following steps: firstly, pre-dispersing salmeterol in an emulsion, coating salmeterol in a polymer while polymerizing a monomer vinyl acetate and polyvinyl alcohol to form degradable oleophylic and hydrophilic polymer nanoparticles, and then adding a penetrant, a pressure-sensitive adhesive and the like to prepare the patch. According to the invention, firstly, salmeterol is encapsulated by adopting a hydrophilic and oleophylic polymer, the amphiphilic polymer has better compatibility with auxiliary materials in the patch, the medicine can be more uniformly distributed in the patch after the medicine is encapsulated, meanwhile, salmeterol has better lipophilicity, and in combination with better lipophilicity and hydrophilicity of the polymer, the medicine can be more uniformly distributed in the patch; therefore, the prepared patch has better permeability to the skin, meanwhile, the problem that the medicine is re-crystallized from a supersaturated state is avoided, and the acting effect of the patch is better.

The invention belongs to the technical field of biological medicines, and particularly relates to application of salmeterol in preparation of a medicine for treating non-small cell lung cancer. It is found for the first time that the compound salmeterol is an effective inhibitor of asparagine synthetase (ASNS), and the compound salmeterol inhibits the biological activity and / or protein expression level of the ASNS by directly targeting the ASNS, so that a synthetic pathway of endogenous asparagine of cells is blocked. On the basis, salmeterol directly targets ASNS, inhibits the activity and / or expression level of ASNS, blocks synthesis of endogenous asparagine, and further inhibits tumor cell proliferation and induces tumor cell apoptosis. The new application of salmeterol as the ASNS inhibitor is innovatively found, a new mechanism, a new medicine and a new scheme are provided for treatment of the non-small cell lung cancer, and the salmeterol has important clinical application prospects and scientific value.

The present invention relates to a transdermal composition comprising a compound selected from the group comprising formoterol, salbutamol, salmeterol, fenoterol, mixtures thereof or salts thereof, and dimethylsulfoxide. The present invention further relates to a composition comprising a compound selected from the group comprising salbutamol, clenbuterol or salts thereof, and comprising at least one of water or a monohydric alcohol.

The invention provides a liquid pharmaceutical composition comprising: a) at least one long-acting muscarinic receptor antagonist (LAMA) selected from the group consisting of glycopyrronium bromide, ipratropium bromide, umiclidium bromide, and revefenacin; b) at least one long-acting adrenoceptor agonist (LABA) selected from the group consisting of formoterol fumarate, salmeterol xinofoate; alformoterol tartarate, and vilanterol trifenate; and c) at least one inhaled corticosteroid (ICS) selected from the group consisting of beclomethasone dipropionate, budesonide, ciclesonide, fluticasone furoate, and fluticasone propionate; and wherein the composition is in the form of a solution for aerosolization, as well as methods and devices for use of the composition.